Research Out of Mexico Validates Medical Marijuana’s (MJNA) RSHO-X™

Medical Marijuana Inc. (OTC: MJNA) received further validation of its Real Scientific Hemp Oil-X™ (“RSHO-X™”) after Dr. Carlos G. Aguirre Velazquez released a new study conducted on children with refractory epilepsy. In the study, he reported 60% of 53 children treated with cannabidiol (“CBD”) oil experienced a reduction in seizures, including 16% that were completely free of seizures and 51% that experienced a moderate to important improvement.

“This is such exciting news for our company and we are honored and humbled to witness this new work performed by D. Velazquez,” said Medical Marijuana, Inc.’s Chief Executive Officer Dr. Stuart Titus. “We are proud to be the first company with CBD products approved by the Mexico government, and thrilled to see the results that our products are producing for the quality of life for families that otherwise had no options.”

In this article, we will take a closer look at these study results and why they could translate into a significant opportunity for the company, its shareholders, and those suffering from epilepsy.

Securing an Import License

Medical Marijuana Inc. secured the right to import its RSHO-X™ CBD oil into Mexico in early February 2016 when the Health Department of Mexico (“COFEPRIS”) issued the country’s first-ever government permits for the drug. The move followed a series of Congressional hearings in January where the company joined other advocates in Mexico City to lobby for the legalization of the drug for treating numerous serious medical conditions.

The market for cannabinoid-based treatments in Mexico could be roughly the same size as California’s enormous market – and President Pena Nieto has already proposed legalizing medical marijuana and easing limits for personal use of the drug. In late-2015, the Mexican Supreme Court also ruled that marijuana for recreational use could be legalized under the Constitution, which could pave the way for a dramatically changed market.

In addition to Mexico, the company has been successful in securing the rights to import its CBD oils into a number of other countries around the world, including Paraguay, Brazil, and Puerto Rico. These licenses permit the import of RSHO™ to treat a growing number of medical indications, including epilepsy, Parkinson’s disease, chronic pain, and cancer pain and related symptoms – a much more diverse array than prescription cannabinoids.

Promising Study Results

Dr. Carlos G. Aguirre Velazquez’s study showed promising results when it comes to using CBD oils to treat children with refractory epilepsy. Of the 53 children included in the study, 16% reported no more seizures at all, while 60% reported a reduction in seizures. In addition, 83% reported improvements in emotions, 88% saw improved cognition, 77% reported better sleep, and 60% had improved feeding, suggesting strong improvements in quality of life.

These results confirm similar findings by other companies studying the effects of cannabinoids on medical conditions like epilepsy. For instance, GW Pharmaceuticals plc’s (NASDAQ: GWPH) Epidiolex is a cannabinoid that has been approved in several countries for the treatment of seizures with a 36.5% reduction in monthly motor seizures. A number of other companies are similarly developing and studying drugs targeting epilepsy and related conditions.

Interestingly, Dr. Aguirre Velazquez’s RSHO-X™ study found no adverse side-effects among the 53 children enrolled in the study, compared to nearly 80% of Epidiolex that reported issues. These side-effects included decreased appetite (19%), diarrhea (19%), fatigue (13%) and convulsion (11%). Serious events were reported in nearly a third of the patients, while 3% of those enrolled ended up discontinuing treatments because of these effects.

Looking Ahead

Medical Marijuana Inc. (OTC: MJNA) represents a compelling opportunity for investors interested in the cannabis industry. With growing distribution of its RSHO-X™ CBD oils, the company has the opportunity to reach a wide market of patients without conducting expensive clinical trials. The botanical version of CBD may also have fewer side-effects and similar efficacy profiles compared to pharmacological versions based on Dr. Aguirre Velazquez’s research.

For more information, visit the company’s website at

About the Author

Stuart Smith is the CEO and Founder of is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about and their services, please visit